Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析

目的 探讨Luminal B型乳腺癌TEC新辅助化疗的疗效及其影响因素。方法 对2016年1月~2018年6月于我院行4次TEC方案新辅助化疗的81例Luminal B型乳腺癌患者的临床病历资料进行回顾性分析，分析临床病理特征及相关指标的改变与疗效的相关性。结果 4周期新辅助化疗pCR率为4.94%，临床疗效与临床分期存在统计学意义（P＜0.05），是否获得pCR与年龄、BMI、绝经状态、原发肿瘤大小、肿瘤部位、确诊时淋巴结状态、PR、P53、Ki67均无统计学意义（P＞0.05）。而除去4例获得pCR的患者，剩余77例乳腺癌患者新辅助化疗前后ER、PR的表达状态、Ki67指数的差异具有统计学意义（P＜0.05）。结论 临床分期晚的患者新辅助化疗疗效相对较差，Ki67可能是乳腺癌新辅助化疗疗效的预测指标。

Analysis of the Efficacy and Influencing Factors of Neoadjuvant Chemotherapy for Luminal B Breast Cancer

Objective To investigate the efficacy and influencing factors of neoadjuvant chemotherapy for Luminal B breast cancer. Methods The clinical medical records of 81 patients with Luminal B breast cancer who underwent 4 TEC regimen neoadjuvant chemotherapy in our hospital from January 2016 to June 2018 were retrospectively analyzed. The clinicopathological features and related indicators were analyzed. Correlation of efficacy. Results The pCR rate of neoadjuvant chemotherapy was 4.94%. The clinical efficacy and clinical stage were statistically significant (P<0.05). Whether pCR and age, BMI, menopausal status, primary tumor size, tumor location, and lymph node status at diagnosis were obtained. There were no significant differences in PR, P53 and Ki67 (P>0.05). Except for 4 patients with pCR, the expression of ER and PR and the Ki67 index of 77 patients with breast cancer before and after neoadjuvant chemotherapy were statistically significant (P<0.05). Conclusion Neoadjuvant chemotherapy is relatively ineffective in patients with late clinical stage. Ki67 may be a predictor of neoadjuvant chemotherapy for breast cancer.